文献速递自身免疫性与大疱性皮肤病

儿童自身免疫性大疱性疾病长期演变特征:38例回顾性研究

Long-term evolving profile of childhood autoimmune blistering diseases: Retrospective study on 38 children.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-14

结果显示总体预后良好,34/38例达完全缓解,但除大疱性类天疱疮外可出现晚期复发,长期随访必要,局部糖皮质激素常有效。

要点

  • 儿童自身免疫性大疱性疾病总体预后良好,34/38例达完全缓解。
  • 除大疱性类天疱疮外,其他类型可出现晚期复发,需长期随访。
  • 局部糖皮质激素单用或联合其他治疗常有效。

核心结论

  • 儿童自身免疫性大疱性疾病总体预后良好,但除大疱性类天疱疮外,长期随访是必要的,因为复发可能较晚。
  • 局部糖皮质激素单用或联合其他治疗常有效。
  • 与原发性免疫缺陷的关联提示需考虑儿童潜在的免疫异常。

主要发现

  • 38例完成随访者中,29例至少有一次复发。
  • 晚期复发见于2例疱疹样皮炎和6例天疱疮(7-34个月)。
  • 38例中34例达完全缓解,随访时间4.4年(0.08-19.5)。
  • 达完全缓解的平均时间为30.5个月(6-114个月)。
  • 仅1例获得性大疱性表皮松解症报告晚期鼻粘连;2例观察到与原发性免疫缺陷的关联。

关键数值与推荐

  • 38例中34例达完全缓解,随访时间4.4年(0.08-19.5)。
  • 达完全缓解的平均时间为30.5个月(6-114个月)。
  • 平均治疗时间为30.6个月,因疾病类型而异。
  • 局部糖皮质激素单用有效7例,联合其他治疗用于19例完全缓解者。

临床怎么用

  • 儿童自身免疫性大疱性疾病应长期随访,警惕除大疱性类天疱疮外的晚期复发。
  • 局部糖皮质激素可作为单用或联合治疗的有效选择。
  • 对患儿应考虑筛查潜在的原发性免疫缺陷或免疫异常。

局限性

  • 单中心回顾性研究,样本量有限(最终分析38例)。
  • 长期结局通过电话问卷获取,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune bullous dermatoses (AIBDs) in children are uncommon, and their long-term evolution remains unknown. OBJECTIVE: The aim of this retrospective study was to characterize the long-term prognosis of AIBDs that started during childhood. METHODS: We conducted a monocentric retrospective study, in the French dermatology centre, by including all children affected by AIBDs. The long-term outcome was obtained through a phone call questionnaire. RESULTS: Sixty-three patients were included from January 1993 to December 2015, 34 female and 29 males: 27 Linear immunoglobulin A disease (LAD), 12 bullous pemphigoid (BP), 12 pemphigus, 8 herpetiform dermatitis (DH) and 4 epidermolysis bullosa aquisita (EBA). The mean age was 4.7 years old. Twenty-five patients were lost during the follow-up. For the 38 remaining patients, the mean follow-up duration for all pathologies was 6.6 years. Twenty-nine of them had at least one relapse. Late relapses were observed in two cases of DH and six cases of pemphigus (7-34 months). The mean treatment duration was 30.6 months with variability according to the AIBDs. Topical corticosteroids were used alone, effectively, for seven patients and in association with other treatment in 19 patients in complete remission. Complete remission was noted in 34/38 children with a follow-up of 4.4 years (0.08-19.5). The mean duration to complete remission was 30.5 months (6-114 months). Late nasal synechiae were reported in one EBA only. There was no significant associated comorbidity, but an association with a primary immune deficiency (PID) was observed in two cases. CONCLUSION: Childhood AIBDs appear to be of good overall prognosis but a long-term follow-up is mandatory, as relapses can be late, except for BP. The use of topical corticosteroids is frequently effective alone or in association. The association with PID leads to think about the possibility of a possible underlying dysimmunity in the child.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Welfringer-Morin A, Bekel L, Bellon N, et al. Long-term evolving profile of childhood autoimmune blistering diseases: Retrospective study on 38 children. J Eur Acad Dermatol Venereol. 2019. PMID: 30702174. doi:10.1111/jdv.15456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。